Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Alpha 1 Antitrypsin Deficiency Clinical Trials

A listing of Alpha 1 Antitrypsin Deficiency medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (10) clinical trials

What is Alpha-1 Antitrypsin Deficiency? Alpha-1 Antitrypsin Deficiency is a genetic (inherited) condition that may result in serious lung disease in adults and/or liver disease at any age. Alpha-1 Antitrypsin Deficiency occurs when there is a lack of a protein in the blood called alpha-1 antitrypsin, or AAT. AAT is ...

Phase N/A

A stage 1, prospective, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Alpha 1-proteinase Inhibitor (A1P1) augmentation therapy in subjects with A1P1 Deficiency and chronic obstructive pulmonary disease (COPD). This study is an approximately 2 year study that will evaluate the safety and effectiveness of the FDA ...

Phase N/A

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human) Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses ...

Phase

Alpha-1 Foundation Research Registry

The Registry was established in 1997 by the Alpha-1 Foundation to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1. Located at the Medical University of South Carolina (MUSC) in Charleston, the Registry employs procedures that ensure the most stringent confidentiality of participants. The ...

Phase N/A

Alpha-1 Coded Testing(ACT) Study

Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications. All genetic tests have risks and possible benefits. The ACT study evaluates the population demographics, reasons for testing, and outcomes through a confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are ...

Phase N/A

Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)

Cholestasis is a rare condition that involves a reduction or obstruction of bile flow from the liver to the small intestine. When bile flow is hindered, a waste product pigment called bilirubin can escape into the bloodstream and build up to harmful levels. This may lead to the easily recognizable ...

Phase N/A

Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema

All patients who suffer from this disease are followed every 6 months during a 5 years period. FEV1 decline is the primary endpoint. Quality of life assessed using the Saint George's Respiratory Questionary is recorded too.

Phase N/A

Stage 1 Study of ARALAST NP and GLASSIA in A1PI

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and Chronic obstructive pulmonary disease (COPD).

Phase

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

The study protocol proposes to assess participants' clinical status based on the results of spirometry tests that are performed by the patient's managing physician as a routine part of clinical care of individuals with AATD within +/- 6 months of the initial diagnosis, subjects' St. George's Respiratory Questionnaire (SGRQ) at ...

Phase N/A

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

The primary objective is to determine if Carbamazepine therapy in patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency leads to a significant reduction in the hepatic accumulation of ATZ. The other objectives are: To determine whether Carbamazepine treatment reduces hepatic fibrosis in alpha-1-antitrypsin deficient patients with severe liver disease. ...

Phase